The risk of tuberculosis infection in 410 Saudipatients receiving adalimumab therapy
BACKGROUND: Adalimumab is a fully humanized monoclonal antibody inhibitor of tumor necrosis factor-a used to treat various autoimmune disorders. Adalimumab poses a risk for tuberculosis (TB) infection, especially in countries where TB is endemic. OBJECTIVE: Determine the rate of TB infection after a...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | article |
| Language: | EN |
| Published: |
King Faisal Specialist Hospital and Research Centre
2021
|
| Subjects: | |
| Online Access: | https://doaj.org/article/509a4578978a4742b75b0e1ee2ff05a3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|